PART I . Overview We are a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer ("NK") cell therapies. Our company was founded on the belief that engineered NK cell therapies can transform the lives of patients by offering therapies that are clinically meaningful, broadly accessible and unencumbered by the safety concerns often associated with other cell therapy approaches. Our lead pipeline program is NKX019, a chimeric antig...
Q2 FY2026 — expected 2026-08-13
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-25 | 2025-12-31 | 0001787400-26-000006 | EDGAR | 89K words |
| 2025-03-26 | 2024-12-31 | 0000950170-25-045262 | EDGAR | — |
| 2024-03-21 | 2023-12-31 | 0000950170-24-034735 | EDGAR | — |
| 2023-03-16 | 2022-12-31 | 0000950170-23-008523 | EDGAR | — |
| 2022-03-17 | 2021-12-31 | 0000950170-22-004095 | EDGAR | — |
| 2021-03-25 | 2020-12-31 | 0001564590-21-015517 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001787400-26-000017 | EDGAR | — |
| 2025-11-10 | 2025-09-30 | 0001193125-25-274304 | EDGAR | 64K words |
| 2025-08-12 | 2025-06-30 | 0001193125-25-178964 | EDGAR | — |
| 2025-05-14 | 2025-03-31 | 0000950170-25-071455 | EDGAR | — |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123395 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0000950170-24-096186 | EDGAR | — |
| 2024-05-09 | 2024-03-31 | 0000950170-24-056980 | EDGAR | — |
| 2023-11-09 | 2023-09-30 | 0000950170-23-062091 | EDGAR | — |
| 2023-08-10 | 2023-06-30 | 0000950170-23-040953 | EDGAR | — |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021277 | EDGAR | — |
| 2022-11-09 | 2022-09-30 | 0000950170-22-023845 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0000950170-22-016892 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-10 | 0001193125-26-342402 | EDGAR | — |
| 2026-03-26 | 0001787400-26-000008 | EDGAR | 1K words |
| 2026-03-25 | 0001787400-26-000005 | EDGAR | — |
| 2025-11-10 | 0001193125-25-274261 | EDGAR | — |
| 2025-08-12 | 0001193125-25-178949 | EDGAR | — |
| 2025-06-06 | 0000950170-25-082717 | EDGAR | — |
| 2025-05-14 | 0000950170-25-071399 | EDGAR | — |
| 2025-03-26 | 0000950170-25-045231 | EDGAR | — |
| 2024-11-07 | 0000950170-24-123340 | EDGAR | — |
| 2024-08-13 | 0000950170-24-096163 | EDGAR | — |
101 total filings indexed. 73 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001787400 |
| Ticker | NKTX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.nkartatx.com |
| Listed | 2020-07-10 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/NKTX (~200 tokens, structured JSON with cryptographic provenance)